Zofran
Primary Mediastinal B-cell Lymphoma (PMBCL)
Miltenyi Biomedicine GmbHPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Primary Mediastinal B-cell Lymphoma (PMBCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BB |
Eloxatin City of Hope Medical Center | Phase 2 | BB |
Bendamustine Miltenyi Biomedicine GmbH | Phase 2 | B |
Ari-0001 Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 | B |
Tocilizumab Jonsson Comprehensive Cancer Center | Phase 1/2 | CCC |
View all 11 →
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →